Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in ...

Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

Glenmark Pharmaceuticals launches a generic ophthalmic solution for glaucoma in the US market, adding to its growing ...

According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million.

Glenmark launches Latanoprost Ophthalmic Solution, targeting $113.5 million market, showcasing commitment to quality eye care ...

Glenmark Pharmaceuticals (NSE: GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% ...

Glenmark Pharma introduces generic Xalatan ophthalmic solution, 0.005% in US: Our Bureau, Mumbai Friday, February 14, 2025, 12:15 Hrs [IST] Glenmark Pharmaceuticals Inc., USA (Gle ...

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution.

Clear Channel Outdoor Holdings, Inc., (NYSE:CCO) announced today that Scott Wells, Chief Executive Officer of Clear Channel ...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine ...

Dry Eye Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future grow ...

Occasionally, treatments come along that are of greater interest to patients than to doctors.Drops for treating presbyopia ...